FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 313 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Workout Wednesdays – Leg Exercises Part 3 June 24, 2020 Immune interception represents an exciting opportunity to stop cancer in its... September 16, 2025 Studying Molecular Subtypes of Peritoneal Metastases in Gastric Cancer September 6, 2021 Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... June 7, 2022 Load more HOT NEWS Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced... A new target to slow down ageing and reduce blood cancer... Tumor Signatures May Help Explain Global Differences in Kidney Cancer Rates Elucidating a Risk of Developing Second Primary Malignancy During and After...
